Results showed that T22-PE24-H6 displays potent in vitro antitumor activity only in AML patient samples showing high CXCR4 expression but no effect in BM samples with low receptor expression (Figure 5D). This evidence concerns the gene CXCR4 and acute myeloid leukemia.